Stay updated with breaking news from Drug Pricing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/U6LJYY5RTVPCRK3ZS3IGHWIYCY.jpg)
Abbye E. Alexander, Christopher J. Tellner and Talya Van Embden of Kaufman Dolowich discuss litigation over the 340B Drug Pricing Program, intended to help health care providers serve financially vulnerable patients.
Shortages Caused by Broken Financial System and Misguided Public Policies that Plague Generic, Sterile, Injectable Cancer Drugs, says COA
Hospitals’ participation in Medicare’s 340B Drug Pricing Program may increase costs for cancer patients with commercial insurance.
CMS is proposing a $9 billion lump sum payment to hospitals participating in the 340B Drug Pricing Program to make them whole from unlawful payment cuts from 2018-2022
The pharmaceutical industry’s relentless, astronomically expensive campaign to smear the 340B Drug Pricing Program — one of the world’s most important humanitarian programs — knows no bounds. Our healthcare safety net is under attack.